Navigation Links
Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
Date:8/13/2013

SAN DIEGO, Aug. 13, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced results for the second quarter and six months ended June 30, 2013. The company will host a conference call today to provide an operational update and discuss financial results, its first as a public company.

"The second quarter was transformative for Ambit.  We successfully completed our initial public offering, which put us on solid financial footing to continue the clinical development of quizartinib, our lead drug candidate," said Michael Martino, president and Chief Executive Officer. "Our primary goal is to make this potentially important new therapy available to patients with acute myeloid leukemia (AML), who are in need of better treatment options."

Second Quarter Highlights and Recent Events

  • Raised net proceeds of approximately $83 million after completion of an initial public offering of common stock, including $25 million in a concurrent private placement with existing investors
  • Presented results from the Phase 2 ACE study of quizartinib in patients with relapsed or refractory AML at the annual meeting of the American Society of Clinical Oncology (ASCO) and at the 18th Congress of the European Hematology Association
  • Completed top line analyses from the Phase 2b clinical trial of quizartinib
  • Held a Type C meeting with the FDA in June.  FDA requested additional information and analyses be presented at end of Phase 2 (EOP2) meeting
  • Submitted four abstracts to the American Society of Hematology (ASH) for the annual meeting in December 2013
  • Quizartinib Program UpdateThe Company has completed preliminary top line analyses of the Phase 2b clinical trial of qu
    '/>"/>

    SOURCE Ambit Biosciences Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
    2. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
    3. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
    4. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
    5. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
    6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
    7. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
    8. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
    9. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
    10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
    11. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... Switzerland , October 1, 2014 /PRNewswire/ ... Clinical Genomics and Next Generation Sequencing (NGS) data analysis, ... to run full cystic fibrosis analysis in a single ... and characterisation of all types of variants in a ... Until now, it has not been possible to ...
    (Date:9/30/2014)... Sept. 30, 2014 This report analyzes the worldwide ... following Product Categories: Enteral Feeding Pumps, Nasogastric Tubes, and Others. ... US Canada, Japan , Europe ... America , and Rest of World. Annual estimates and ... a six-year historic analysis is provided for these markets. ...
    (Date:9/30/2014)... -- Hologic, Inc. (NASDAQ: HOLX ), today announced ... Executive Officer, will preside over the NASDAQ Stock Market ... of Breast Cancer Awareness Month. In his remarks, Mr. ... important benefits of Hologic,s 3D Mammography technology, the only ... to traditional mammography. This is the ninth ...
    Breaking Medicine Technology:Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3
    ... N.J. , April 26 Watson Pharmaceuticals, ... the U.S. Court of Appeals for the Federal Circuit ... District Court decision that the asserted claims of ALZA,s ... invalid.  The original suit by ALZA Corporation and McNeil-PPC, ...
    ... April 26 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... calls focused on the drugs in Isis, development pipeline.  The second call of ... Wednesday, April 28, 2010 at 12:00 p.m. ET .  This ... , , ...
    Cached Medicine Technology:Watson Says Appeals Court Affirms Concerta(R) Patent Invalid 2Watson Says Appeals Court Affirms Concerta(R) Patent Invalid 3Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 2Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 3
    (Date:10/1/2014)... October 01, 2014 Insuranceragents.info has ... a good life insurance plan for vulnerable family members. ... vulnerable family members. Providers in the family should always ... cause financial hardships for the rest of the family. ... policies. Families can benefit more from temporary coverage or ...
    (Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
    (Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
    (Date:10/1/2014)... Jersey City, NJ (PRWEB) October 01, 2014 ... sticking with their intentions to lose weight and their dieting ... in unhealthy, fatty foods. Including hormone diet treatments ... not only allows patients to see fast and effective weight ... diet and begin forming healthy habits to maintain their weight ...
    (Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
    Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
    ... the form of percutaneous coronary intervention (PCI) is now ... infarction. New European guidelines issued in November 2008 emphasised ... to restore blood flow to the heart and improve ... in patients with stable coronary artery disease; PCI has ...
    ... Construction Company, the nation,s leading builder of healthcare facilities, ... proceed with the $42 million Phase Two expansion to ... start in March 2009 with completion scheduled for March ... plant, emergency rooms, ICU, CCU, three operating rooms and ...
    ... PARK, Ill., Feb. 6 Abbott ( NYSE: ABT ... Antitrust,Improvements Act of 1976 (HSR) applicable to Abbott,s cash ... common stock of Advanced Medical,Optics (AMO) expired last night ... The expiration of the HSR waiting period satisfies ...
    ... of 7 HIV+ Patients Receiving Dapsone Therapy at Significant ... IRVINE, Calif., Feb. 6 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, today announced that a ... Medicine 38th Critical Care Congress suggests providers should consider ...
    ... revenues increase by 35% over same period in ... are in Canadian dollars unless otherwise noted),BELLEVILLE, ON, ... (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, ... of its 2009 fiscal year, ending December 31, ...
    ... a new study shows that losing weight is perhaps the ... disorders, according to a new study in the American ... the American Thoracic Society,s three peer-reviewed journals. , Weight ... fancy high-tech treatment, but it is an exciting therapy for ...
    Cached Medicine News:Health News:Efficacy of stents is improved when their placement is determined by arterial blood flow measurement 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review 2Health News:Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review 3Health News:New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia 2Health News:New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia 3Health News:New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia 4Health News:Bioniche Reports Fiscal 2009 Second Quarter 2Health News:Bioniche Reports Fiscal 2009 Second Quarter 3Health News:Bioniche Reports Fiscal 2009 Second Quarter 4Health News:Bioniche Reports Fiscal 2009 Second Quarter 5Health News:Bioniche Reports Fiscal 2009 Second Quarter 6Health News:Bioniche Reports Fiscal 2009 Second Quarter 7Health News:Bioniche Reports Fiscal 2009 Second Quarter 8Health News:Bioniche Reports Fiscal 2009 Second Quarter 9Health News:Losing weight can cure obstructive sleep apnea in overweight patients 2
    ... sensitivity (threshold) testing provides clinically beneficial ... ophthalmic conditions. Dark adaptometry is useful ... retinal degenerations, senile miosis, high myopia, ... conditions, while whole-field scotopic sensitivity has ...
    ... The MFERG is available in conjunction with ... UTAS-E3000mf or EPIC-4000 or as a stand-alone ... visual electrodiagnostic test uses a software controlled ... to stimulate many areas of the retina ...
    ... Amplifier (UBA-4204) from LKC Technologies, ... amplification and complete electrical isolation ... problems of DC drifting, 50/60Hz ... make the amplifier ideal for ...
    ... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
    Medicine Products: